Kyle Mikson
Stock Analyst
(1.08)
# 2,624
Out of 4,648 analysts
59
Total ratings
34.04%
Success rate
-21.3%
Average return
Main Sectors:
Stocks Rated by Kyle Mikson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Maintains: Buy | $145 → $150 | $122.92 | +22.03% | 4 | Oct 29, 2024 | |
| EXAS Exact Sciences | Maintains: Buy | $75 → $95 | $72.18 | +31.62% | 8 | Oct 29, 2024 | |
| CSTL Castle Biosciences | Maintains: Buy | $35 → $42 | $33.56 | +25.17% | 3 | Oct 29, 2024 | |
| TXG 10x Genomics | Maintains: Buy | $32 → $20 | $16.55 | +20.85% | 6 | Oct 10, 2024 | |
| LUCD Lucid Diagnostics | Maintains: Buy | $3 | $0.94 | +219.11% | 3 | Aug 13, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $3.5 → $3 | $2.47 | +21.70% | 7 | Aug 8, 2024 | |
| TTOO T2 Biosystems | Maintains: Hold | $3 → $5 | $0.80 | +523.29% | 3 | Jul 30, 2024 | |
| GH Guardant Health | Maintains: Buy | $30 → $38 | $23.26 | +63.37% | 4 | Jun 4, 2024 | |
| AKYA Akoya Biosciences | Maintains: Buy | $10 → $6 | $2.72 | +120.59% | 2 | May 14, 2024 | |
| QTRX Quanterix | Maintains: Buy | $32 → $25 | $13.49 | +85.32% | 4 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $3.5 | $1.42 | +146.48% | 2 | Mar 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $210 → $120 | $154.67 | -22.42% | 5 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $3.5 → $2 | $0.76 | +164.90% | 2 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $2 | $0.61 | +230.58% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $2.47 | +183.39% | 1 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $49 | $1.03 | +4,692.99% | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $1.76 | +979.55% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.88 | +17,042.86% | 1 | Jan 29, 2021 |
Natera
Oct 29, 2024
Maintains: Buy
Price Target: $145 → $150
Current: $122.92
Upside: +22.03%
Exact Sciences
Oct 29, 2024
Maintains: Buy
Price Target: $75 → $95
Current: $72.18
Upside: +31.62%
Castle Biosciences
Oct 29, 2024
Maintains: Buy
Price Target: $35 → $42
Current: $33.56
Upside: +25.17%
10x Genomics
Oct 10, 2024
Maintains: Buy
Price Target: $32 → $20
Current: $16.55
Upside: +20.85%
Lucid Diagnostics
Aug 13, 2024
Maintains: Buy
Price Target: $3
Current: $0.94
Upside: +219.11%
Pacific Biosciences of California
Aug 8, 2024
Maintains: Buy
Price Target: $3.5 → $3
Current: $2.47
Upside: +21.70%
T2 Biosystems
Jul 30, 2024
Maintains: Hold
Price Target: $3 → $5
Current: $0.80
Upside: +523.29%
Guardant Health
Jun 4, 2024
Maintains: Buy
Price Target: $30 → $38
Current: $23.26
Upside: +63.37%
Akoya Biosciences
May 14, 2024
Maintains: Buy
Price Target: $10 → $6
Current: $2.72
Upside: +120.59%
Quanterix
Apr 29, 2024
Maintains: Buy
Price Target: $32 → $25
Current: $13.49
Upside: +85.32%
Mar 4, 2024
Reiterates: Buy
Price Target: $3.5
Current: $1.42
Upside: +146.48%
Nov 10, 2023
Downgrades: Hold
Price Target: $210 → $120
Current: $154.67
Upside: -22.42%
Sep 25, 2023
Downgrades: Hold
Price Target: $3.5 → $2
Current: $0.76
Upside: +164.90%
Aug 16, 2023
Maintains: Overweight
Price Target: $3 → $2
Current: $0.61
Upside: +230.58%
Nov 15, 2022
Maintains: Buy
Price Target: $8 → $7
Current: $2.47
Upside: +183.39%
Mar 30, 2021
Initiates: Overweight
Price Target: $49
Current: $1.03
Upside: +4,692.99%
Jan 29, 2021
Initiates: Overweight
Price Target: $19
Current: $1.76
Upside: +979.55%
Jan 29, 2021
Initiates: Overweight
Price Target: $150
Current: $0.88
Upside: +17,042.86%